Base Metals Investing Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Base Metals Investing OpRegen® Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
Base Metals Investing Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
Base Metals Investing Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
